Here's what life science startups were named most promising at the recent Rice Alliance Texas Life Science Forum.. Getty Images

Houston hosted an annual meeting of the minds that included thoughtful discussions, presentations, panels, and startup pitches within the life science industry.

The Texas Life Science Forum, organized and hosted by the Rice Alliance and BioHouston, took place on November 6 at Rice University's Bioscience Research Collaborative. Throughout the day, over 50 life science startups pitched to the audience. At the end of the forum, 10 startups — most of which are based in Houston — were recognized as being the most promising.

Here's what life science startups you should be keeping an eye out for.

Abilitech Medical

abilitech

Photo via abilitechmedical.com

A St. Paul, Minnisota-based medical device company, Abilitech Medical develops assistive technology to Multiple sclerosis, Muscular Dystrophy, Parkinson's and stroke patients. The first product, Alibitech Assist, will be cleared by the FDA in 2020, with other devices to follow in 2022 and 2023.

AgilVax

agilvax

Photo via agilvax.com

Based in Albuquerque, New Mexico, AgilVax is a biopharmaceutical company that works with chemotherapy, checkpoint and KRAS inhibitors to fight various cancers. The company's AX09 is an immunotherapeutic that is headed for human clinical trials in 2020. Another product, M5, is a monoclonal antibody currently in preclinical trials.

Altoida

altoida

Photo via altoida.com

Altoida, based in Houston, has created a medical device that uses artificial intelligence and augmented reality to collect functional and cognitive data in patients to determine their risk Mild Cognitive Impairment from Alzheimer's Disease. The Altoida Neuro Motor Index has been cleared by the FDA and CE and detects cognitive decline with a 94 percent diagnostic accuracy six to 10 years ahead of the onset of symptoms.

ColubrisMX

Photo via Pexels

Houston-based ColubrisMX makes surgical robots specializing in minimally invasive and endoluminal surgeries. The company's team of engineers and surgeons works adjacent to the Texas Medical Center.

Cord Blood Plus

stem cell

Photo via Getty Images

Cord Blood Plus, based in Galveston, is working to commercialize its human umbilical cord blood stem cell technology. The company's primary mission is to use its research and treatment on breast cancer patients undergoing chemotherapy in order to prevent infections, speed up recovery, and shorten hospital stays.

CorInnova

CorInnova

Photo via CorInnova.com

Another Houston company, CorInnova is a medical device company that has developed a cardiac assist device to treat heart failure without many of the consequences from standard treatment. The device is able to self expand and gently compress the heart in sync with the heartbeat.

Mesogen

mesogen

Photo via Mesogen.com

Mesogen, which is based in The Woodlands, is in the business of using a patient's own cells to grow a human kidney for transplant. The tissue engineering technology allows for the creation of a kidney in less than a year with less risk of transplant rejection and a better quality of life over dialysis treatment.

Saranas

Courtesy of Saranas

Houston-based Saranas has created its Early Bird device to more quickly and more accurately detect bleeding in the human body. The company, which underwent successful clinical trials last year, recently received FDA clearance and launched the device in the United States.

Stream Biomedical

stream biomedical

Photo via streambiomedical.com

Stream Biomedical Inc. is tapping into a therapeutic protein that has proven to be neuroprotective and neuroreparative. The Houston company is aiming to apply the treatment in acute stroke cases and later for traumatic brain injury, Alzheimer's, and dementia cases.

VenoStent

Photo via venostent.com

Houston-based VenoStent has created a device that allows a successful stent implementation on the first try. VenoStent's SelfWrap is made from a shape-memory polymer that uses body heat to mold the stent into the vein-artery junction.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.

New Texas Stock Exchange officially begins trading in Dallas

Welcome to Y'all Street

Two-step aside, New York Stock Exchange and Nasdaq. The Dallas-based Texas Stock Exchange, nicknamed Y’all Street, just kicked off live trading with five stocks — and lots of Lone Star ambition.

“The Texas Stock Exchange aims to revitalize competition for [stock] issuers, establish the premier venue for listings, and create a world-class trading platform for all market participants,” the exchange says in a fact sheet.

The exchange — whose Texas-influenced nickname is a nod to New York City’s Wall Street — has collected at least $275 million in investments. The roughly 90 financial backers of TXSE include Bank of America, BlackRock, Charles Schwab, Citadel Securities, Dell Family Office, Fortress, Goldman Sachs, and JPMorgan Chase.

Representatives of TXSE couldn’t be reached for comment. On its website, the exchange calls itself “the most well-capitalized equities exchange to ever be approved” by the U.S. Securities and Exchange Commission (SEC).

Not to be outdone, NYSE has launched Dallas-based NYSE Texas and Nasdaq has expanded its presence in Dallas.

Y’all Street adds to Dallas-Fort Worth’s rising status as a major hub for financial services, with The Wall Street Journal naming North Texas the country’s second biggest financial hub after New York City.

“A homegrown national exchange means more jobs, more investment, and more growth opportunities for businesses and communities across the Lone Star State,” Gabriela von zur Muehlen, senior vice president and chief policy officer at the Texas Association of Business, told The Texas Tribune.

Bulent Temel, an associate professor of practice in economics at the University of Texas at San Antonio, told Texas Standard that TXSE “is going to boost the credibility of the Texas economy.”

Texas’ estimated gross domestic product (GDP), a yardstick for the size of an economy, climbed to a record-setting $2.9 trillion in 2025, making it the state with the second highest GDP after California. DFW’s estimated GDP in 2023 stood at $744.6 billion, eclipsing the GDP of many countries.

“The center of gravity for American capitalism is now headquartered in the Boom Belt,” Abbott proclaimed in April, referring to an 11-state region (including Texas) in the South and Southeast that’s seeing tremendous economic and population growth. “The Texas Stock Exchange is the natural extension of that capitalism. It ensures that capital markets will reflect the quadrant that is driving American growth.”

---

This article originally appeared on CultureMap.com.

Orion vehicle manager reflects on Artemis II, looks to 2028 moon mission

Q&A

Humanity is finally headed back to the moon after more than half a century. This year's launch of the Artemis II mission in the Orion spacecraft put four crew members in lunar orbit and tested the new ship developed by Lockheed Martin.

Everything went smoothly, safely returning astronauts home, but there is always room to improve. InnovationMap chatted via email with Orion vehicle manager Branelle Rodriguez, shortly after a talk at The Ion, for insight on how Orion might perform in the future as the next lunar landing approaches in early 2028.

InnovationMap: How satisfied are you with the way Orion operated on this past mission?

Branelle Rodriguez: Orion performed exceptionally well during Artemis II, successfully demonstrating critical spacecraft capabilities, including life support systems, displays and controls, and executing manual piloting operations. Artemis II brought humans back to the moon, achieving key exploration and scientific imagery, while validating systems essential for future Artemis missions.

IM: What is the most important thing you learned about improving Orion for the next mission?

BR: The Artemis II mission provided invaluable insights into crew operations and spacecraft performance in a deep-space environment. With every mission, NASA applies lessons learned to continuously improve Orion’s operations, validate design and ensure mission readiness. Artemis II offered our first opportunity to evaluate several new systems and gain a deeper understanding of what it is like for astronauts to live and work inside the spacecraft. The operational, technical and human factors data collected are being integrated across the program to refine future missions, reduce risk and enhance overall mission success.

IM: How has Orion helped the mission to explore space?

BR: Orion is one of NASA’s foundational elements for human deep space exploration—not only supporting the mission but serving as a core component of it. It is currently the only spacecraft capable of carrying crew on deep space missions and returning them safely to Earth from the high speeds required from the vicinity of the moon. No other spacecraft has the technology to endure the extremes that come with human deep-space travel, such as advanced environmental and life support, navigation, communications, radiation shielding, and the world’s largest ablative heat shield to protect the astronauts during reentry into Earth’s atmosphere. Orion has already taken astronauts to explore space farther than ever before—252,756 miles from Earth— and will carry crews to the moon on future missions to explore the lunar South Pole region. The astronauts’ observations, samples, and data collected on these future missions will expand our understanding of our solar system and home planet.

---

This conversation has been edited for brevity and clarity.